13th Annual Cardiometabolic Health Congress (CHMC) is organized by Tarsus CNS and will be held from Oct 24 - 27, 2018 at Sheraton Boston Hotel, Boston, Massachusetts, United States of America.
The target audience for this medical event is advanced level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk including cardiologists, endocrinologists, diabetologists, lipidologists, pharmacists, primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), and other allied health professionals. This CME Conference has been approved for a maximum of 27+ AMA PRA Category 1 Credits.
More than one-third of the population has at least one cardiometabolic risk factor - dyslipidemia, CVD, hypertension, diabetes, and/or obesity. Now in its 13th year, the Cardiometabolic Health Congress is the largest, US-based, multidisciplinary conference focused solely on the management of cardiometabolic risk and the prevention of cardiovascular and metabolic disease. The 3 ½- day event offers today's busy healthcare professionals a one-of-a-kind opportunity to learn real-world solutions they can integrate immediately into their clinical practices.
The 2018 CMHC will translate the latest cutting edge medical research into practical, clinical strategies for preventing, delaying, diagnosing, treating, and managing cardiovascular and metabolic disorders. The goal is to provide the medical community with evidence based interventions that they can apply immediately in clinical practice to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.
Learning Objectives :
After completing this activity, the participant should be better able to:
• Describe the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life
• Identify the symptoms of ID using appropriate markers in HF patients in order to diagnose ID
• Discuss the updated ACC/AHA/HFSA recommended guidelines for the management of iron deficiency in patients with HF
• Review evidence from major clinical trials assessing the efficacy and safety of iron supplementation in HF patients to improve patient outcomes and reduce HF hospitalizations
• Risk Factors for Dyslipidemia, Atherosclerosis, and Cardiovascular Disease
• The Effect of Circadian Rhythm on Obesity and CVD
• Diet Quality, Quantity, and Beyond in Cardiometabolic Disorders
• Insulin and Non-Insulin Therapies for Diabetes Management
• Challenging Patient Cases in Hypertension, Cardio-renal, and Heart Failure
Physicians: USD 495,
Allied Health Professionals: USD 295,
Fellows/ Residents/ Students: USD 195,
Industry: USD 695
Speakers: Aldo Peixoto, William White, George Bakris, James de Lemos, Matthew Budoff, Vera Bittner, Paul Ridker, Peter Libby, Pamela Morris, Ana Barac, Andrea Dunaif, Pam Taub, Nieca Goldberg, JoAnn Manson, Pam Taub, Jay Skyler, Keith Ferdinand, Deepak Bhatt, C. Ronald Kahn, Irl Hirsch, Anne Peters, John Buse, Stephen Devries, Mary-Elizabeth Patti, James Hill, Robert Kushner
Additional details will be posted as soon as they are available.